DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

Phase 2

Active, not recruiting

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Elafibranor 120 mg
Drug: Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 120 mg
Drug: Placebo Matched to Elafibranor 80 mg

First Posted Date: 2022-11-25

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 68

Registration Number: NCT05627362

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Piedmont Hospital - Piedmont Transplant Institute, Atlanta, Georgia, United States
🇬🇧
Aberdeen Royal Infirmary NHS Grampian Grampian Health Board, Aberdeen, United Kingdom

and more 59 locations

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Phase 3

Completed

Conditions: Locally Advanced Prostate Cancer
Advanced Prostate Cancer
Metastatic Prostate Cancer

Interventions: Drug: Triptorelin pamoate (embonate) salt

First Posted Date: 2022-10-21

Last Posted Date: 2024-08-28

Lead Sponsor: Ipsen

Target Recruit Count: 195

Registration Number: NCT05590793

Locations: 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, China

and more 33 locations

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: elafibranor

First Posted Date: 2022-10-03

Last Posted Date: 2025-02-20

Lead Sponsor: Ipsen

Target Recruit Count: 34

Registration Number: NCT05564208

Locations: 🇫🇷
BIOTRIAL, Rennes, France

A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)

Completed

Conditions: Spastic Hemiparesis
Muscle Spasticity

First Posted Date: 2022-09-19

Last Posted Date: 2023-04-18

Lead Sponsor: Ipsen

Target Recruit Count: 25

Registration Number: NCT05546190

Locations: 🇺🇸
Rancho Los Amigos National Rehab, Downey, California, United States
🇺🇸
MedStar National Rehabilitation Network, Washington, District of Columbia, United States

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Elafibranor

First Posted Date: 2022-09-16

Last Posted Date: 2025-02-20

Lead Sponsor: Ipsen

Target Recruit Count: 48

Registration Number: NCT05543369

Locations: 🇺🇸
Collaborative Neuroscience Research LLC, Long Beach, California, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin embonate 22.5 mg

First Posted Date: 2022-07-14

Last Posted Date: 2024-08-01

Lead Sponsor: Ipsen

Target Recruit Count: 147

Registration Number: NCT05458856

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie, Liège, Belgium

and more 36 locations

A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

Completed

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2022-07-06

Last Posted Date: 2023-07-18

Lead Sponsor: Ipsen

Target Recruit Count: 252

Registration Number: NCT05444933

Locations: 🇫🇷
CHU Besançon, Besançon, France
🇫🇷
Hôpital Edouard Herriot, Lyon, France
🇫🇷
CHU Amiens, Amiens, France

and more 24 locations

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Completed

Conditions: Acromegaly

First Posted Date: 2022-06-24

Last Posted Date: 2025-01-31

Lead Sponsor: Ipsen

Target Recruit Count: 129

Registration Number: NCT05431803

Locations: 🇨🇳
The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU), Guangzhou, China
🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou, China
🇨🇳
The First Hospital of China Medical University (CMU1H), Shenyang, China

and more 9 locations

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Irinotecan liposome injection
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2022-05-20

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 177

Registration Number: NCT05383352

Locations: 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺
Flinders Medical Centre, Bedford Park, Australia
🇦🇺
Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia

and more 33 locations

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment

Active, not recruiting

Conditions: Early-stage Breast Cancer

First Posted Date: 2022-05-17

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 450

Registration Number: NCT05377684

Locations: 🇮🇹
Istituto Oncologico del Mediterraneo (IOM), Viagrande, Italy
🇮🇹
Ospedale "S. Bortolo", Vicenza, Italy
🇮🇹
Policlinico S. Orsola - Malpighi, Bologna, Italy

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy